F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comGranules India Limited, a leading pharmaceutical manufacturing company, has emerged as a strong player in the global pharmaceutical supply chain. Known for its cost-efficient operations, API (Active Pharmaceutical Ingredients) production, and strong global partnerships, the company continues to attract long-term investors.
In this article, we’ll explore Granules India share price targets from 2025 to 2030, current stock details, shareholding pattern, and future growth outlook.
| Detail | Value |
|---|---|
| Open | ₹470.00 |
| Previous Close | ₹467.25 |
| Day’s High | ₹512.90 |
| Day’s Low | ₹467.90 |
| VWAP | ₹497.26 |
| Market Capitalization | ₹12,037 Cr |
| Volume | 14,034,083 |
| Value (Lacs) | 69,623.09 |
| Beta (Volatility) | 1.09 |
| UC Limit | ₹560.70 |
| LC Limit | ₹373.80 |
| 52-Week High | ₹721.00 |
| 52-Week Low | ₹422.00 |
| All-Time High | ₹721.00 |
| All-Time Low | ₹2.53 |
| Face Value | ₹1 |
| Book Value Per Share | ₹141.25 |
| Dividend Yield | 0.30% |
| 20D Avg Volume | 1,645,613 |
| 20D Avg Delivery (%) | 43.7 |
Granules India is a Hyderabad-based pharmaceutical company engaged in manufacturing APIs, pharmaceutical formulation intermediates, and finished dosages. The company has a strong presence in key export markets, including the US and Europe, making it a preferred partner for several global pharmaceutical giants.
Key Highlights:
Strong global presence across APIs and formulations
Focus on cost leadership and bulk drug manufacturing
Consistent dividend-paying track record
Improved R&D capabilities for higher-margin products
Resilient against domestic and international demand shifts
| Investor Type | Holding (%) |
|---|---|
| Promoters | 38.82% |
| Retail & Others | 25.20% |
| Foreign Institutions | 13.24% |
| Mutual Funds | 12.24% |
| Other Domestic Institutions | 10.50% |
This shareholding pattern indicates healthy promoter confidence and significant institutional interest.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 520 | 560 |
| 2026 | 580 | 640 |
| 2027 | 650 | 720 |
| 2028 | 700 | 780 |
| 2029 | 760 | 850 |
| 2030 | 820 | 920 |
These targets are based on fundamentals, historical performance, and future growth opportunities in both domestic and global pharma markets.
By 2025, Granules India may see recovery in its margins with stronger demand in APIs and formulations.
Why?
Steady demand for generic medicines globally
Resilient operating margins due to cost leadership
Institutional investors increasing stake
Investment Advice: Consider staggered investments, as pharma demand remains defensive even in volatile markets.
In 2026, the company is expected to expand its formulations capacity and focus more on higher-margin products.
Why?
Expansion in US and European markets
Rising contribution from finished dosages
Healthy balance sheet and strong promoter holding
Investment Advice: A good pick for medium-term investors; consider holding for compounding benefits.
By 2027, exports and R&D-driven products will likely push the share price upward.
Why?
Growth in exports
Stronger R&D pipeline delivering better profitability
Focus on regulated market approvals
Investment Advice: Hold long-term; reinvest dividends for compounding growth.
Granules may cross the ₹700 mark as revenue diversification accelerates.
Why?
Increasing presence in value-added products
Global partnerships with leading pharma companies
Consistent performance in quarterly results
Investment Advice: Continue SIP or staggered buying for wealth creation.
By 2029, the company’s growth in branded generics could help maintain upward momentum.
Why?
Expanding domestic business
Diversified export market presence
Stable promoter and institutional holding
Investment Advice: Excellent for medium- to long-term investors seeking steady returns.
By 2030, Granules India is expected to strengthen its leadership in the API and formulations segment globally.
Why?
Strong leadership and corporate governance
Robust global demand for cost-effective generics
Better EPS growth supported by efficient operations
Investment Advice: Ideal stock for long-term portfolios; strong potential for wealth creation.
Yes. Granules India is a strong long-term bet, especially for investors looking at the pharmaceutical sector. With a strong promoter base, steady institutional holding, and global growth opportunities, the stock shows promising returns potential.
Key Reasons to Invest:
Strong global demand for APIs and formulations
Cost efficiency and bulk manufacturing edge
Promoter confidence and institutional support
Attractive growth potential in regulated markets
⚠️ Risks to Watch Out For:
Regulatory challenges in global markets
Currency fluctuations impacting export margins
Competition from other generic manufacturers
Granules India has built a solid foundation in the pharmaceutical industry with its cost-efficient business model and global reach. With a market cap of ₹12,037 Cr and strong investor backing, the company has the potential to deliver steady returns.
Currently, the share price hovers around ₹470, and analysts project that Granules India could touch ₹920 by 2030. For long-term investors, it represents a strong opportunity for portfolio diversification.
1. What is the next target of Granules India?
The next target is projected around ₹520 – ₹560 for 2025, depending on market conditions.
2. Is Granules India a good buy right now?
Yes, for long-term investors, pharma stocks like Granules India provide defensive growth opportunities.
3. What will be the future outlook of Granules India?
The outlook remains strong due to growing global demand for APIs, formulations, and generics.
4. What is the share price target for Granules India in 2025?
Granules India is expected to trade between ₹520 – ₹560 in 2025.
5. What is the current Granules India share price?
As of August 29, 2025, the price is around ₹470.
6. Is it a good time to buy Granules India shares now?
Yes, considering its valuation and growth potential, investors can accumulate during dips.
7. Should I buy Granules India stock for the long term?
Yes, it is ideal for long-term investors seeking steady compounding growth in pharma.
8. How much has Granules India increased from its 52-week low?
It has increased from ₹422 (52-week low) to ₹470 levels, showing steady momentum.
9. How do I invest in Granules India?
You can buy shares through NSE and BSE using any registered stockbroker.
10. What is Granules India’s shareholding pattern?
Promoters hold 38.82%, with mutual funds and foreign institutions also showing strong participation.
???? Disclaimer: This article is for educational purposes only. Please consult a financial advisor before investing.
Register & Login